XML 70 R56.htm IDEA: XBRL DOCUMENT
v3.23.3

Segment Data Segment Data - Revenues by Geographic Areas (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021
Segment Reporting Information [Line Items] |  |  |
Revenues | $ 19,372 | $ 18,870 | $ 19,131
Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 9,502 | 8,841 | 8,361
Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 5,133 | 5,564 | 6,530
Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 4,736 | 4,464 | 4,239
United States |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 11,113 | 10,722 | 10,371
United States | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 5,488 | 4,950 | 4,544
United States | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 2,377 | 2,732 | 2,980
United States | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 3,247 | 3,040 | 2,847
Non-US |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 8,258 | 8,148 | 8,760
Non-US | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 4,014 | 3,891 | 3,817
Non-US | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 2,756 | 2,833 | 3,550
Non-US | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,489 | 1,424 | 1,392
Medication Delivery Solutions | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 4,293 | 4,308 | 4,101
Medication Delivery Solutions | United States | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 2,519 | 2,483 | 2,253
Medication Delivery Solutions | Non-US | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,774 | 1,825 | 1,848
Medication Management Solutions | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 2,980 | 2,533 | 2,432
Medication Management Solutions | United States | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 2,303 | 1,935 | 1,863
Medication Management Solutions | Non-US | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 677 | 598 | 570
Pharmaceutical Systems | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 2,229 | 2,001 | 1,828
Pharmaceutical Systems | United States | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 666 | 533 | 428
Pharmaceutical Systems | Non-US | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,563 | 1,468 | 1,400
Integrated Diagnostic Solutions | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 3,624 | 4,185 | 5,225
Integrated Diagnostic Solutions | United States | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,774 | 2,190 | 2,477
Integrated Diagnostic Solutions | Non-US | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,850 | 1,995 | 2,748
Biosciences | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,509 | 1,379 | 1,305
Biosciences | United States | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 603 | 542 | 503
Biosciences | Non-US | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 906 | 838 | 802
Surgery | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,497 | 1,400 | 1,296
Surgery | United States | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,159 | 1,094 | 1,023
Surgery | Non-US | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 338 | 306 | 274
Peripheral Intervention | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,865 | 1,759 | 1,711
Peripheral Intervention | United States | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,016 | 960 | 931
Peripheral Intervention | Non-US | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 849 | 799 | 780
Urology and Critical Care | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,374 | 1,305 | 1,232
Urology and Critical Care | United States | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,073 | 986 | 894
Urology and Critical Care | Non-US | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | $ 301 | $ 319 | $ 338

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_MedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_LifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_InterventionalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_MedicationDeliverySolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_MedicationManagementSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_PharmaceuticalSystemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_IntegratedDiagnosticSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_BiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_PeripheralInterventionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_UrologyandCriticalCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |